Schering-Plough of the USA has said that a US Federal Trade Commissionadministrative law judge has ruled that patent litigation settlements relating to the firm's controlled-release supplement K-Dur 20 (potassium chloride) complied with the law in every respect.
In 1995, Upsher-Smith Laboratories and ESI Lederle filed separate Abbreviated New Drug Applications with the US Food and Drug Administration for generic versions of K-Dur 20, and S-P brought actions against both companies alleging product infringement. However, in each case, both parties settled out of court.
S-P said that separate patent litigation settlements, reached with U-S and ESI Lederle, offered consumer benefits by facilitating the introduction of generic equivalents to K-Dur several years prior to its patent expiry date of 2006. Under the terms of the settlement consumers have been able to buy the generic equivalent of K-Dur since 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze